Lin BioScience (ROCO:6696) Change In Receivables : NT$-25.02 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Change In Receivables?

Lin BioScience's change in receivables for the quarter that ended in Jun. 2023 was NT$0.07 Mil. It means Lin BioScience's Accounts Receivable declined by NT$0.07 Mil from Dec. 2022 to Jun. 2023 .

Lin BioScience's change in receivables for the fiscal year that ended in Dec. 2023 was NT$-25.02 Mil. It means Lin BioScience's Accounts Receivable increased by NT$25.02 Mil from Dec. 2022 to Dec. 2023 .

Lin BioScience's Accounts Receivable for the quarter that ended in Jun. 2023 was NT$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lin BioScience's liquidation value for the six months ended in Jun. 2023 was NT$1,775.34 Mil.

Lin BioScience Change In Receivables Historical Data

The historical data trend for Lin BioScience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Change In Receivables Chart

Lin BioScience Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

7.99

-1.48

1.46

-25.02

Lin BioScience Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial										-	1.33	0.13	0.07	-25.09

Lin BioScience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-25.02 Mil.

Lin BioScience (ROCO:6696) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lin BioScience's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Lin BioScience's accounts receivable are only considered to be worth 75% of book value:

Lin BioScience's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1954.815	-	179.477	+	0.75 * 0	+	0.5 * 0
=	1,775.34

Lin BioScience Change In Receivables Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Lin BioScience (ROCO:6696) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110

Website

https://www.linbioscience.com

Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines